Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 6/20 | 0.50 |
| ▸ | LAP3 | P28838 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ANPEP | P15144 | 4/20 | 0.37 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3936724 | 1.00 | FDPS (0.50) | FDPSLAP3LMNAANPEPERAP1 | |
| SCHEMBL5572484 | 0.97 | FDPS (0.48) | FDPSLAP3LMNAANPEPERAP1 | |
| SCHEMBL4436425 | 0.84 | FDPS (0.42) | FDPSLAP3LMNAANPEPERAP1 | |
| SCHEMBL5059565 | 0.79 | FDPS (0.46) | FDPSLAP3LMNAANPEPERAP1 | |
| SCHEMBL6663397 | 0.79 | FDPS (0.38) | FDPSLAP3LMNA | |
| SCHEMBL7511455 | 0.77 | LMNA (0.45) | FDPSLAP3LMNAALDH1A1 | |
| SCHEMBL16091906 | 0.74 | FDPS (0.52) | FDPSLAP3LMNAANPEPERAP1 | |
| SCHEMBL5318557 | 0.72 | FDPS (0.46) | FDPSLAP3LMNAANPEPERAP1 | |
| SCHEMBL6132043 | 0.72 | LAP3 (0.46) | FDPSLAP3LMNAMETAP1ADRB3 | |
| SCHEMBL5489929 | 0.72 | LAP3 (0.46) | FDPSLAP3LMNAMETAP1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | KIACTA SARL (CH) | 2006-06-01 | — | — | US | disclosed |
| US-6670399-B2 | Contacting a blood vessel wall cell with an A beta 40 inhibitor, such that cerebral amyloid angiopathy is inhibited | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2003-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | APP, PYGB, MAPT | FDPS 1920/4885LAP3 1400/4885LMNA 1103/4885 |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CSGALNACT1, CD44 | FDPS 4116/4885LAP3 1256/4885LMNA 2481/4885 |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CD44, CSGALNACT1 | FDPS 4229/4885LAP3 1185/4885LMNA 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.